AU2003299972C1 - Methods and reagents for the enhancement of virus transduction in the bladder epithelium - Google Patents

Methods and reagents for the enhancement of virus transduction in the bladder epithelium Download PDF

Info

Publication number
AU2003299972C1
AU2003299972C1 AU2003299972A AU2003299972A AU2003299972C1 AU 2003299972 C1 AU2003299972 C1 AU 2003299972C1 AU 2003299972 A AU2003299972 A AU 2003299972A AU 2003299972 A AU2003299972 A AU 2003299972A AU 2003299972 C1 AU2003299972 C1 AU 2003299972C1
Authority
AU
Australia
Prior art keywords
composition
bladder
enhancing agent
oncolytic virus
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU2003299972A
Other languages
English (en)
Other versions
AU2003299972B2 (en
AU2003299972A1 (en
Inventor
David Frey
Bahram Memarzadeh
Nagarajan Ramesh
Dechao Yu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CG Oncology Inc
Original Assignee
Cold Genesys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cold Genesys Inc filed Critical Cold Genesys Inc
Publication of AU2003299972A1 publication Critical patent/AU2003299972A1/en
Assigned to BIOSANTE PHARMACEUTICALS, INC reassignment BIOSANTE PHARMACEUTICALS, INC Request for Assignment Assignors: CELL GENESYS, INC.
Application granted granted Critical
Publication of AU2003299972B2 publication Critical patent/AU2003299972B2/en
Publication of AU2003299972C1 publication Critical patent/AU2003299972C1/en
Assigned to Cold Genesys, Inc reassignment Cold Genesys, Inc Request for Assignment Assignors: BIOSANTE PHARMACEUTICALS, INC
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2003299972A 2002-12-26 2003-12-24 Methods and reagents for the enhancement of virus transduction in the bladder epithelium Expired AU2003299972C1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/327,869 2002-12-26
US10/327,869 US7459154B2 (en) 2002-12-26 2002-12-26 Methods and reagents for the enhancement of virus transduction in the bladder epithelium
PCT/US2003/041379 WO2004060303A2 (en) 2002-12-26 2003-12-24 Methods and reagents for the enhancement of virus transduction in the bladder epithelium

Publications (3)

Publication Number Publication Date
AU2003299972A1 AU2003299972A1 (en) 2004-07-29
AU2003299972B2 AU2003299972B2 (en) 2010-05-13
AU2003299972C1 true AU2003299972C1 (en) 2010-12-16

Family

ID=32680762

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003299972A Expired AU2003299972C1 (en) 2002-12-26 2003-12-24 Methods and reagents for the enhancement of virus transduction in the bladder epithelium

Country Status (9)

Country Link
US (7) US7459154B2 (enExample)
EP (1) EP1583502A4 (enExample)
JP (1) JP2006512398A (enExample)
KR (1) KR20050088231A (enExample)
CN (1) CN1753618A (enExample)
AU (1) AU2003299972C1 (enExample)
CA (1) CA2510903A1 (enExample)
NZ (1) NZ540732A (enExample)
WO (1) WO2004060303A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7459154B2 (en) * 2002-12-26 2008-12-02 Cell Genesys, Inc. Methods and reagents for the enhancement of virus transduction in the bladder epithelium
US20050059613A1 (en) * 2003-07-08 2005-03-17 Bahram Memarzadeh Compositions and methods for the enhanced uptake of therapeutic agents through the bladder epithelium
KR20070121644A (ko) * 2005-01-14 2007-12-27 유리젠, 인코포레이티드 하부 요로 치료용 키트 및 개선된 조성물
ES2564518T3 (es) 2006-09-14 2016-03-23 Bahram Memarzadeh Monolaurato de sucralosa y monomiristato de sucralosa, formulaciones farmacéuticas, estuches de diagnóstico y métodos de tratamiento
US20110086005A1 (en) * 2008-05-27 2011-04-14 Oncolytics Biotech Inc. Modulating interstitial pressure and oncolytic viral delivery and distribution
US20130052165A1 (en) * 2010-01-12 2013-02-28 Livnat Bangio Methods of Producing Adenovirus Vectors and Viral Preparations Generated Thereby
DE102011085501A1 (de) * 2011-10-31 2013-05-02 Söring GmbH Elektrochirurgievorrichtung
JP6954648B2 (ja) * 2015-10-19 2021-10-27 シージー オンコロジー， インコーポレイテッド 併用療法による固形腫瘍又はリンパ系腫瘍の治療方法
US11497781B2 (en) * 2016-03-10 2022-11-15 Cg Oncology, Inc. Methods of treating bladder cancer by combination therapy comprising the oncolytic adenovirus CG0070 and an immune checkpoint inhibitor
EP3610026B1 (en) 2017-04-14 2025-05-14 CG Oncology, Inc. Cg0070 for treating bcg resistant bladder carcinoma in situ
WO2020143221A1 (zh) * 2019-01-07 2020-07-16 四川安可康生物医药有限公司 增强系统免疫应答的免疫溶瘤病毒组合药物及其应用
EP4175969A4 (en) * 2020-07-01 2024-07-24 Medimmune, LLC DETERGENT AND METHOD FOR PURIFYING A BIOTHERAPY AGENT
CN113717953B (zh) * 2021-08-05 2024-07-26 北京舜雷科技有限公司 一种减毒黄病属病毒在溶瘤中的应用
WO2025251009A1 (en) * 2024-05-31 2025-12-04 Cg Oncology, Inc. Methods of treating bladder cancer using an oncolytic virus and a transduction-enhancing agent

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US169138A (en) * 1875-10-26 Improvement in folding lounges
JPH01245159A (ja) * 1988-03-28 1989-09-29 Gen Corp:Kk ニューカッスル病ウィルス抗体の検出用プレート及び抗原ウィルスの可溶化方法
US5369095A (en) 1990-02-14 1994-11-29 Alcon Laboratories, Inc. Compositions and method comprising substituted glycosides as mucus membrane permeation enhancers
US6165500A (en) * 1990-08-24 2000-12-26 Idea Ag Preparation for the application of agents in mini-droplets
US5525519A (en) * 1992-01-07 1996-06-11 Middlesex Sciences, Inc. Method for isolating biomolecules from a biological sample with linear polymers
US5368844A (en) 1992-12-16 1994-11-29 Colgate Palmolive Company Antiplaque, antigingivitis, anticaries oral composition
JPH11502233A (ja) * 1995-12-08 1999-02-23 花王株式会社 殺菌剤組成物
US5789244A (en) 1996-01-08 1998-08-04 Canji, Inc. Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems
US20020169138A1 (en) * 1997-10-24 2002-11-14 Southern Research Institute Delivery vehicles for bioactive agents and uses thereof
US6855549B1 (en) * 1998-11-23 2005-02-15 The University Of Iowa Research Foundation Methods and compositions for increasing the infectivity of gene transfer vectors
ATE419338T1 (de) 2000-03-24 2009-01-15 Cell Genesys Inc Menschliche zellspezifische urotheliale regulatorische sequenzen der transkription des uroplakins, dessen vektoren und verwendungsverfahren
US6911200B2 (en) 2000-03-24 2005-06-28 Cell Genesys, Inc. Methods of treating neoplasia with combination of target-cell specific adenovirus, chemotherapy and radiation
IL139708A0 (en) * 2000-11-15 2002-02-10 Amiel Gilad Process of decellularizing biological matrices and acellular biological matrices useful in tissue engineering
AUPR894201A0 (en) * 2001-11-19 2001-12-13 Women's And Children's Hospital Respiratory delivery for gene therapy and lentiviral delivery particle
US7459154B2 (en) * 2002-12-26 2008-12-02 Cell Genesys, Inc. Methods and reagents for the enhancement of virus transduction in the bladder epithelium

Also Published As

Publication number Publication date
KR20050088231A (ko) 2005-09-02
US20080241105A1 (en) 2008-10-02
US20080112932A1 (en) 2008-05-15
CA2510903A1 (en) 2004-07-22
US7267815B2 (en) 2007-09-11
US20080138322A1 (en) 2008-06-12
WO2004060303A3 (en) 2005-11-24
AU2003299972B2 (en) 2010-05-13
AU2003299972A1 (en) 2004-07-29
US20040131590A1 (en) 2004-07-08
EP1583502A4 (en) 2007-01-17
US7459154B2 (en) 2008-12-02
JP2006512398A (ja) 2006-04-13
US20040176318A1 (en) 2004-09-09
US20090068151A1 (en) 2009-03-12
EP1583502A2 (en) 2005-10-12
US20080112931A1 (en) 2008-05-15
WO2004060303A2 (en) 2004-07-22
CN1753618A (zh) 2006-03-29
NZ540732A (en) 2008-01-31

Similar Documents

Publication Publication Date Title
US20080112931A1 (en) Methods and reagents for the enhancement of virus transduction in the bladder epithelium
Wang et al. miR-26a limits muscle wasting and cardiac fibrosis through exosome-mediated microRNA transfer in chronic kidney disease
ES2233995T3 (es) Composiciones que contienen un detergente y un gen supresor de tumores, codificado por un vector adenovirico.
JPH09500524A (ja) 遺伝子治療のためのアデノウイルスベクター
JP2011148834A (ja) インターフェロン耐性腫瘍の処置のための方法および組成物
Iwamoto et al. Pulmonary inflammation associated with repeated, prenatal exposure to an E1, E3-deleted adenoviral vector in sheep
JP4982680B2 (ja) デコリン遺伝子を含む薬剤学的抗腫瘍組成物
Dai et al. Chimeric Ad5/35 oncolytic adenovirus overcome preexisting neutralizing antibodies and enhance tumor targeting efficiency
JP2005508158A (ja) 癌治療のための組成物および方法
ES2550962T3 (es) Proteína E4orf1 de adenovirus Ad36 para prevención y tratamiento de enfermedad de hígado graso no alcohólico
CN116271034B (zh) 靶向ccdc25在制备治疗和/或预防化疗诱导的器官纤维化药物中的应用
US7534424B2 (en) Method of enhancing delivery of a therapeutic nucleic acid
US20100113569A1 (en) Isolated dna fragment of the human a33 promoter and its use to control the expression of a heterologous gene in tumor cells
Zhang et al. S-RBD-modified and miR-486-5p-engineered exosomes derived from mesenchymal stem cells alleviate radiation-induced lung injury and long-term pulmonary fibrosis via suppression of ferroptosis
Larochelle et al. Modulation of coxsackie and adenovirus receptor expression for gene transfer to normal and dystrophic skeletal muscle
WO2026082131A1 (zh) 用于预防及治疗肠道异常增生相关疾病的药物
Xuemei et al. Mesenchymal stem cell–derived exosomal microRNA-34c-5p ameliorates renal pericyte activation by inhibiting core fucosylation
Lewis et al. Systemic Senolysis in Naturally Aged Mice Using a FAST-PLV Gene Therapy Approach
Brandon et al. Effect of administration route on biodistribution and shedding of replication-deficient viral vectors used in gene therapy. A literature study
JP2023532923A (ja) 骨格筋線維の修復を改善するためのリコンビナントヒト酸性スフィンゴミエリナーゼの使用
Jahedi Toxicity and tropism of oncolytic VSV vectors in glioblastoma gene therapy
Parker Cell-mediated Gene Therapy for Liver Disease
Kira et al. Dynamics of Aquaporin 1 and Aquaporin 8 in the Pancreas: An Experimental Study with a Caerulein
Strauss ANALYSIS OF RESISTANCE OF PRIMARY OVARIAN CANCER CELLS TO VIRAL ONCOLYSIS DISSER TAT ION zur Erlangung des akademischen Grades doctor rerum naturalium
CN106267222A (zh) 血管紧张素ⅱ用于改善大分子药物或药物载体的心脏递送

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: BIOSANTE PHARMACEUTICALS, INC

Free format text: FORMER APPLICANT(S): CELL GENESYS, INC.

DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 28 JUL 2010.

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 28 JUL 2010

FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: COLD GENESYS, INC

Free format text: FORMER OWNER WAS: BIOSANTE PHARMACEUTICALS, INC

MK14 Patent ceased section 143(a) (annual fees not paid) or expired